lenacapavir 300 MG Oral Tablet
- RxCUI
- 2625890
- RxNorm name
- lenacapavir 300 MG Oral Tablet
- Display name
- lenacapavir 300 MG Oral Tablet
- Full name
- lenacapavir 300 MG Oral Tablet
- Term type
- PSN
- Status
- DailyMed mapping
- Updated
- 2026-06-04 23:39:25
UNII Substances#
No records found.
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| Sunlenca | LENACAPAVIR SODIUM | Gilead Sciences, Inc. | e5652804-29c4-40d7-aeb2-0142ed2a7b5b | 2026-03-12 | Warnings, Adverse reactions | 2625890 |
| Yeztugo | LENACAPAVIR SODIUM | Gilead Sciences, Inc. | 1c241af1-ce62-4b0a-9eb7-f6b626174f01 | 2026-02-12 | Boxed warning, Warnings, Adverse reactions | 2625890 |
DailyMed RxNorm Mappings#
| Set ID | RxNorm mappings | Terms | SPL version | Label | Effective |
|---|---|---|---|---|---|
| e5652804-29c4-40d7-aeb2-0142ed2a7b5b | lenacapavir 300 MG Oral Tablet [PSN] · lenacapavir 300 MG Oral Tablet [SCD] · lenacapavir 300 MG (as lenacapavir sodium 306.8 MG) Oral Tablet [SY] | 3 | 12 | These highlights do not include all the information needed to use SUNLENCA safely and effectively. See full prescribing information for SUNLENCA. SUNLENCA ® (lenacapavir) tablets, for oral use SUNLENCA ® (lenacapavir) injection, for subcutaneous use Initial U.S. Approval: 2022 | 20260312 |
| 1c241af1-ce62-4b0a-9eb7-f6b626174f01 | lenacapavir 300 MG Oral Tablet [PSN] · lenacapavir 300 MG Oral Tablet [SCD] · lenacapavir 300 MG (as lenacapavir sodium 306.8 MG) Oral Tablet [SY] | 3 | 4 | These highlights do not include all the information needed to use YEZTUGO safely and effectively. See full prescribing information for YEZTUGO. YEZTUGO ® (lenacapavir) tablets, for oral use YEZTUGO ® (lenacapavir) injection, for subcutaneous use Initial U.S. Approval: 2022 | 20260212 |